UNITED STATES

SECURITIES AND EXCHANGE COMMISSION


Washington, D.C.  20549

_____________________________

FORM 8-K/A

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934


Date of Report:

(Date of earliest event reported)

December 10, 2012

____________________________


DIAGNOSTIC IMAGING INTERNATIONAL CORP.

(Exact name of registrant as specified in charter)


NEVADA

(State or other Jurisdiction of Incorporation or Organization)


333-1364363

848 N. Rainbow Blvd. #2494

Las Vegas, Nevada 89107

98-0493698

(Commission File Number)

(Address of Principal Executive Offices and zip code)

(IRS Employer Identification No.)


(877) 331-3444

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))









Item 2.01  Completion of Acquisition or Disposition of Assets.


On December 10, 2012, Diagnostic Imaging International Corp. (the “Company”) acquired all of the outstanding shares of capital stock (the “Shares”) from the stockholders (the “Sellers”) of Schuylkill Open MRI, Inc. (“SOMRI”), a MRI facility located in the greater Philadelphia region, pursuant to the terms of the previously announced Share Purchase Agreement between the Company and the Sellers (the “Share Purchase Agreement”). Pursuant to the terms of the Share Purchase Agreement, the Company paid an aggregate purchase price of $1,825,000 for the Shares, plus a possible earn-out payment of up to $200,000 if certain post-closing revenue targets are met.


In connection with the Share Purchase Agreement, SOMRI entered into a lease agreement with one of the Sellers with respect to the lease of two MRI machines. Under the terms of the lease, SOMRI is to make monthly payments of $11,012.63, plus applicable sales tax, over a period of 48 months.  In addition, SOMRI has agreed to make a one-time lease payment of $125,000 on or before March 30, 2013. The Company has guaranteed all of SOMRI’s obligations under the lease.  At the end of the lease, SOMRI will have the option to purchase the MRI machines for a total purchase price of $1.00.


Item 901  Financial Statements and Exhibits.


(a) Financial Statements of Business Acquired


Audited financial statements as of December 31, 2011 and December 31, 2010.


Unaudited financial statements for the nine months ending September 30, 2012


(b) Pro Forma Financial Information



Unaudited pro forma financial information as of December 31, 2011 and the nine months ending September 30, 2012.











INDEX TO FINANCIAL STATEMENTS



Report of Independent Registered Public Accounting Firm

F-1

Balance Sheets as of December 31, 2011 and 2010

F-2

Income Statements for the years ended December 31, 2011 and 2010

F-3

Statement of Shareholders’ Equity (Deficit) at December 31, 2011 and 2010

F-4

Statements of Cash Flows for the years ended December 31, 2011 and 2010

F-5

Notes to Financial Statements

F-6









Silberstein Ungar, PLLC CPAs and Business Advisors

Phone (248) 203-0080

Fax (248) 281-0940

30600 Telegraph Road, Suite 2175

Bingham Farms, MI 48025-4586

www.sucpas.com


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


Board of Directors and Stockholders

Schuylkill Open MRI, Inc.

Dallas, Texas

We have audited the accompanying balance sheets of Schuylkill Open MRI, Inc. as of December 31, 2011 and 2010, and the related statements of operations, stockholders’ equity, and cash flows for the years then ended. These financial statements are the responsibility of the entity’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Schuylkill Open MRI, Inc. as of December 31, 2011 and 2010, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.


/s/ Silberstein Ungar, PLLC

Silberstein Ungar, PLLC

Bingham Farms, Michigan

November 20, 2012



F-1





SCHUYLKILL OPEN MRI, INC.

BALANCE SHEETS

AS OF DECEMBER 31, 2011 AND 2010

 

 

 

 

 

 

 

2011

 

2010

ASSETS

 

 

 

 

 

Current Assets

 

 

 

 

 

Cash

$

19,259

 

$

14,484

Accounts Receivable

 

212,028

 

 

298,635

Total Current Assets

 

231,287

 

 

313,119

 

 

 

 

 

 

Property and Equipment, net of accumulated depreciation

 

908,741

 

 

1,053,725

 

 

 

 

 

 

Other Assets

 

 

 

 

 

Security Deposit

 

8,140

 

 

8,140

Non-compete Agreement, net of accumulated amortization

 

48,389

 

 

-

Total Other Assets

 

56,529

 

 

8,140

 

 

 

 

 

 

TOTAL ASSETS

 

1,196,557

 

 

1,374,984

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

Current Liabilities

 

 

 

 

 

Accounts Payable

$

37,164

 

$

184,858

Related Party Payable

 

238,056

 

 

166,849

Accrued Expenses

 

296,051

 

 

331,408

Capital Lease Obligation

 

-

 

 

125,386

Current Portion of Long-term Debt

 

73,731

 

 

57,019

Total Current Liabilities

 

645,002

 

 

865,520

 

 

 

 

 

 

Long-term Debt

 

80,240

 

 

97,136

 

 

 

 

 

 

TOTAL LIABILITIES

 

725,242

 

 

962,656

 

 

 

 

 

 

STOCKHOLDERS' EQUITY

 

 

 

 

 

Common Stock - no par value - 1,000,000 shares authorized, 11,666 issued and outstanding

 

1,000

 

 

1,000

Additional Paid-in Capital

 

90,000

 

 

-

Retained Earnings

 

380,315

 

 

411,328

 

 

 

 

 

 

TOTAL STOCKHOLDERS' EQUITY

 

471,315

 

 

412,328

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$

1,196,557

 

$

1,374,984




F-2





SCHUYLKILL OPEN MRI, INC.

STATEMENTS OF OPERATIONS

FOR THE YEARS ENDED DECEMBER 31, 2011 AND 2010

 

 

 

 

 

 

 

2011

 

2010

 

 

 

 

 

 

REVENUE

$

1,787,614 

 

$

2,215,246 

COST OF REVENUE

 

533,531 

 

 

561,422 

GROSS PROFIT

 

1,254,083 

 

 

1,653,824 

 

 

 

 

 

 

OPERATING EXPENSES

 

1,077,524 

 

 

1,537,571 

 

 

 

 

 

 

INCOME FROM OPERATIONS

 

176,559 

 

 

116,253 

 

 

 

 

 

 

OTHER INCOME AND (EXPENSE)

 

(207,572)

 

 

(601,173)

 

 

 

 

 

 

NET LOSS BEFORE INCOME TAXES

 

(31,013)

 

 

(484,920)

 

 

 

 

 

 

PROVISION FOR INCOME TAXES

 

 

 

NET LOSS

$

(31,013)

 

$

(484,920)




F-3





SCHUYLKILL OPEN MRI, INC.

Statements of Changes in Stockholders’ Equity

From January 1, 2010 through December 31, 2011

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

 

 

Common Stock

 

Paid-in

 

Retained

 

 

 

 

Amount

 

Shares

 

Capital

 

Earnings

 

Total

Balance at January 1, 2010

$

1,000 

 

11,666 

 

$

 

$

896,248 

 

$

897,248 

Net Loss

 

 

 

 

 

 

 

 

 

(484,920)

 

 

(484,920)

Balance at December 31, 2010

$

1,000 

 

11,666 

 

$

 

$

411,328 

 

$

412,328 

Forgiveness of Debt

 

 

 

 

90,000 

 

 

 

 

 

90,000 

Net Loss

 

 

 

 

 

 

 

 

 

(31,013)

 

 

(31,013)

Balance at December 31, 2011

$

1,000 

 

11,666 

 

$

90,000 

 

$

380,315 

 

$

471,315 




F-4





SCHUYLKILL OPEN MRI, INC.

STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 2011 AND 2010

 

 

 

 

 

 

 

2011

 

2010

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

Net Loss

$

(31,013)

 

$

(484,920)

Adjustments to Reconcile Net Loss to Net Cash Provided by Operating Activities:

 

 

 

 

 

Bad Debt Expense

 

(21,485)

 

 

323,493 

Depreciation Expense

 

149,754 

 

 

150,608 

Amortization Expense

 

18,611 

 

 

Debt Settlement

 

8,409 

 

 

337,900 

Changes in Assets and Liabilities

 

 

 

 

 

Accounts Receivable

 

108,092 

 

 

(313,180)

Other Assets

 

 

 

1,900 

Accounts Payable

 

5,104 

 

 

133,564 

Accrued Expenses

 

(35,357)

 

 

18,975 

Net Cash Provided by Operating Activities

 

202,114 

 

 

146,072 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 

Acquisitions of Property and Equipment

 

(4,770)

 

 

(38,840)

Net Cash Used in Investing Activities

 

(4,770)

 

 

(38,840)

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

Payments of Capital Lease Obligations

 

(125,386)

 

 

(104,836)

Payments of Long-term Debt

 

(67,184)

 

 

(72,323)

Net Cash Used in Financing Activities

 

(192,570)

 

 

(177,159)

 

 

 

 

 

 

Net Increase (Decrease) in Cash

 

4,775 

 

 

(47,659)

 

 

 

 

 

 

Cash - Beginning of year

 

14,484 

 

 

62,143 

 

 

 

 

 

 

Cash - End of Year

$

19,259 

 

$

14,484 

 

 

 

 

 

 

SUPPLEMENTAL CASH FLOW INFORMATION

 

 

 

 

 

Cash Paid for Interest

$

53,172 

 

$

44,979 

Cash Paid for Income Taxes

$

 

$

 

 

 

 

 

 

SUPPLEMENTAL CASH FLOW INFORMATION

 

 

 

 

 

Non-compete Acquired with Note Payable

$

67,000 

 

$

Debt Forgiveness Contributed to Capital

$

90,000 

 

$




F-5





Schuylkill Open MRI, Inc.

Notes to Financial Statements

December 31, 2011 and 2010


Note 1 Organization and Summary of Significant Accounting Policies


Organization and Basis of Presentation


Schuylkill Open MRI, Inc. (“Schuylkill”, the “Company”, “us”, or “we”) was incorporated on April 24, 2001 under the laws of the State of Texas.  Schuylkill is an independent diagnostic testing facility located in Pottsville, Pennsylvania providing Magnetic Resonance Imaging (MRI) services and which is unaffiliated with any hospital or medical group. Schuylkill officially opened for business and began its operations in March 2003 as an outpatient open MRI facility. Schuylkill currently performs exams on its Siemens Concerto OPEN MRI System utilizing Siemens’ Syngo software (“OPEN MRI”) and its Siemens Magnetom Symphony Quantum 1.5T high field MRI System, also utilizing Syngo software (“Symphony 1.5T high field MRI”).   In April 2012, Schuylkill replaced its Magnetom Vision 1.5T high field MRI (“Vision MRI”) with a refurbished Symphony 1.5T high field MRI. Having both the OPEN MRI System and the Symphony 1.5T high field MRI gives Schuylkill flexibility in the studies it can conduct. Schuylkill uses an electronic health record system to manage its patient medical records.  Schuylkill offers same day, evening and Saturday appointments to accommodate emergency and non-emergency patient’s schedule needs.


Schuylkill participates in most major insurance plans. Schuylkill also accepts Medicare, Medicaid, Worker’s Compensation claims, Personal Injury Protection and Letters of Protection for participating personal injury attorneys in the area. Schuylkill is accredited by the American College of Radiology (“ACR”) and by the Intersocietal Accreditation Commission (or “ICAMRL”).  The ACR certification is valid through March 3rd, 2015 and the ICAMRL certification is valid through March 31st, 2015.


Basis of Presentation


These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year-end is December 31.


Use of Estimates and Assumptions


The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales, expenses and costs recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.


Cash and Cash Equivalents


The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At December 31, 2011 and 2010, cash includes cash on hand and cash in the bank.


Accounts Receivable Credit Risk


The allowance for doubtful accounts is maintained at a level sufficient to provide for estimated credit losses based on evaluating known and inherent risks in the receivables portfolio.


Management evaluates various factors including expected losses and economic conditions to predict the estimated realization on outstanding receivables. As of December 31, 2011 and 2010, the allowance for bad debts was $296,361 and $323,846, respectively.  During the year ended December 31, 2011, we recovered $21,485 of previously written off bad debts.  Bad debt expense for the year ended December 31, 2010 was $323,493.   




F-6




Goodwill and Indefinite Intangible Assets


The Company follows the provisions of Financial Accounting Standard (“FASB”) Accounting Standards Codification (“ASC”) Topic 350 Goodwill and Other Intangible Assets. In accordance with ASC Topic 350, goodwill represents the excess of the purchase price and related costs over the value assigned to net tangible and identifiable intangible assets of businesses acquired and accounted for under the purchase method. Under this standard, goodwill and intangibles with indefinite useful lives are not amortized.  The Company assesses goodwill and indefinite-lived intangible assets for impairment annually during the fourth quarter, or more frequently if events and circumstances indicate impairment may have occurred in accordance with ASC Topic 350. If the carrying value of a reporting unit's goodwill exceeds its implied fair value, the Company records an impairment loss equal to the difference. ASC Topic 350 also requires that the fair value of indefinite-lived purchased intangible assets be estimated and compared to the carrying value. The Company recognizes an impairment loss when the estimated fair value of the indefinite-lived purchased intangible assets is less than the carrying value.  As of December 31, 2011 and 2010, the Company has not acquired any indefinite-lived intangible assets and goodwill.


Revenue Recognition


The Company recognizes revenue at the time of service.


Revenue is accounted for under the guidelines established by SAB 101, Revenue Recognition in Financial Statements, and ASC Topic 605-45, Revenue Recognition – Principal Agent Considerations.


Cost of Sales


Cost of sales includes fees paid to radiologists for Teleradiology services and system usage costs.


Impairment of Long-Lived Assets


In accordance with ASC Topic 360, Property, Plant and Equipment, property, plant, and equipment, and purchased intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.


No impairment loss was recorded for the years ended December 31, 2011 and 2010.


Amortization and Depreciation


Depreciation and amortization are calculated using the straight-line method over the following useful lives:


Medical Equipment – 5 – 7 years


Furniture and Fixtures – 5 – 7 years


Leasehold Improvements – 39 years


Fair Value of Financial Instruments


The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties other than in a forced sale or liquidation.


The carrying amounts of the Company’s financial instruments, including cash, accounts receivable, accounts payable and accrued liabilities, and income taxes payable approximate fair value due to their most maturities.




F-7




Fair Value Measurements


The hierarchy below lists three levels of fair values based on the extent to which inputs used in measuring fair value is observable in the market. We disclose and categorize each of our fair value measurement items that we recorded at fair value on a recurring basis in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:


• Level 1—inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Our Level 1 non-derivative investments primarily include domestic and international equities, U.S. treasuries and agency securities, and exchange-traded mutual funds. Our Level 1 derivative assets and liabilities include those traded on exchanges.


• Level 2—inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques (e.g. the Black-Scholes model) for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, foreign exchange rates, and forward and spot prices for currencies and commodities. Our Level 2 non-derivative investments consist primarily of corporate notes and bonds, mortgage-backed securities, certificates of deposit, certain agency securities, foreign government bonds, and commercial paper. Our Level 2 derivative assets and liabilities primarily include certain over-the-counter options, futures, and swap contracts.


• Level 3—inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models. Our Level 3 non-derivative assets primarily comprise investments in certain corporate bonds. We value these corporate bonds using internally developed valuation models, inputs to which include interest rate curves, credit spreads, stock prices, and volatilities. Unobservable inputs used in these models are significant to the fair values of the investments. The Company Level 3 derivative assets and liabilities primarily comprise derivatives for foreign equities. In certain cases, market-based observable inputs are not available and the company uses management judgment to develop assumptions to determine fair value for these derivatives.


The company does not have assets and liabilities that are carried at fair value on a recurring basis.


Income Taxes


The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes.  This statement prescribes the use of the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.


Recent Accounting Updates


Recent accounting updates that the Company has adopted or that will be required to adopt in the future are summarized below.


On December 31, 2011, the Company adopted updates issued by the Financial Accounting Standards Board (FASB) to the authoritative hierarchy of GAAP. These changes establish the FASB Accounting Standards Codification (ASC) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP. Rules and interpretive releases of the Securities and Exchange Commission (“SEC”) under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. The FASB will no longer issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts; instead the FASB will issue Accounting Standards Updates. Accounting Standards Updates will not be authoritative in their own right as they will only serve to update the Codification. These changes and the Codification itself do not change GAAP. Other than the manner in which new accounting guidance is referenced, the adoption of these changes had no impact on the Financial Statements.


The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.


Updates issued but not yet adopted


The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.




F-8




Note 2. Property and Equipment


Property and equipment are stated at cost. At December 31, 2011 and 2010, the major classes of property and equipment were as follows:


 

December 31,

2011

 

December 31,

2010

Medical Equipment

$

1,017,450 

 

$

1,012,680 

Furniture and Fixtures

 

39,180 

 

 

39,180 

Leasehold Improvements

 

946,803 

 

 

946,803 

Less: Accumulated Depreciation

 

(1,094,692)

 

 

(944,938)

Property and Equipment - Net

$

908,741 

 

$

1,053,725 


Depreciation expense was $149,754 and $150,608 for the years ended December 31, 2011 and 2010, respectively.


Note 3. Lease Commitments


During 2011, the Company extended their current facilities lease for an additional five years.  The lease called for initial lease payments of $4,390 per month with annual increases based on the larger of 2% or the Consumer Price Index as defined.  As December 31, 2011, the monthly lease payment was $5,185.  Total lease expense, including late fees and incidental charges, for the years ended December 31, 2011 and 2010 was $62,121 and $65,140, respectively.


Note 4. Related Party Payables and Expenses


As of December 31, 2011 and 2010, the Company owed related entities $238,056 and $166,849, respectively.


Of these amounts, the Company owed Metiscan Holdings, Inc.(“Holdings”) $236,207 and $159,749, as of December 31, 2011 and 2010, respectively. Holdings is a majority shareholder and is operated by the Company’s management team.  The Company pays Holdings a management fee equal to 5% of earnings each month. During the years ended December 31, 2011 and 2010, the Company recorded management fee expense of $407,560 and $380,474, respectively.


The Company leases all its employees from an employee leasing company, Shoreline Employment Services, Inc., (“Shoreline”).  Shoreline is operated by the Company’s management team.  As of December 31, 2011 and 2010, the Company had overpaid Shoreline $493.  As of December 31, 2010, the Company owed Shoreline $9,000. During the years ended December 31, 2011 and 2010, the Company recorded employee leasing expense of $463,304 and $598,800, respectively.


From time to time, the Company is required to reimburse Bridgepoint Partners, LLC (“Bridgepoint”) for business expenses paid on behalf of the Company.  Bridgepoint is operated by a member of the Company’s management team.  As of December 31, 2011 and 2010, the Company owed Bridgepoint $2,342 and $0, respectively.


During the year ended December 31, 2010, the Company had advanced $1,900 to FirstView EHR (“FirstView”).  FirstView is operated by the Company’s management team.  The advance was repaid in 2011.


Note 5. Accrued Expenses


As of December 31, 2011 and December 31, 2010, the accrued expenses of the Company were $296,051 and $331,408, respectively.


Of this amount, $124,334 and $119,344, as of December 31, 2011 and 2010, respectively, was due to the state of Pennsylvania for unpaid corporate income taxes.


The balance of, $171,717 and $212,064, as of December 31, 2011 and 2010, respectively, was due to the federal government for unpaid corporate income taxes.


Note 6. Obligations Under Capital Lease


On January 1, 2008, the Company entered into a Master Equipment Lease Agreement with Tygris Asset Finance in the amount of $492,970 to finance the purchase of the Company’s Vision MRI located at its facility as well as the leasehold improvements that were made to the facility to accommodate the equipment. This “dollar -buyout” lease has a term of four (4) years at a rate of eight and four tenths of a percent (8.40%) per annum beginning on January 1, 2008 and maturing on January 1, 2012. The monthly payment on this lease was $11,076.




F-9




The lease was paid in full on December 14, 2011 and no future minimum lease payments remain at December 31, 2011.The gross amount of equipment held under capital leases totals $861,383 ($0 net book value after accumulated depreciation of $861,383) at December 31, 2011 and 2010.


Note 7. Long-Term Debt


On May 5, 2009, the Company borrowed $190,000 from JPMorgan Chase Bank and issued a promissory note that calls for a term of four (4) years at a rate of six and a tenth of a percent (6.10%) per annum beginning on June 5, 2009 and maturing on May 5, 2013. The loan was established to refinance the Company’s OPEN MRI that is located at its facility. The monthly payment on this promissory note is $4,479. As of December 31, 2011 and 2010, the unpaid balance of this note was $68,545 and $116,519, respectively.


On June 19, 2009, the Company borrowed $50,000 from an individual and issued a promissory note that calls for a term of five (5) years at a rate of ten percent and one-half of one percent (10.5%) per annum beginning on July 10, 2009, and maturing on April 10, 2014. The monthly payment on this promissory note is $1,074. As of December 31, 2011 and 2010, the unpaid balance of this note was $28,248 and $37,636, respectively.


On February 28, 2011, the Company entered into a non-compete agreement with a former employee and issued a promissory note in the amount of $67,000 that calls for a term of five (5) years at a rate of six percent (6%) per annum beginning on April 1, 2011, and maturing on March 1, 2016. The monthly payment on this promissory note is $1,295. As of September 30, 2012, the unpaid balance of this note was $47,910.


Following are maturities of the long –term debt in convertible notes for each of the next 5 years:


December 31, 2012

 

$

73,731

December 31, 2013

 

 

38,272

December 31, 2014

 

 

24,497

December 31, 2015

 

 

14,901

December 31, 2016

 

 

2,570

Total

 

$

153,971


Interest expense related to long-term debt for the years ended December 31, 2011 and 2010 was $11,162 and $12,416, respectively.


Note 8. Other Income and (Expense)


During the years ended December 31, 2011 and 2010, the Company recorded $207,572 and $601,173 in other expense items, net of other income, respectively.


During the year ended December 31, 2011 the Company incurred $8,409 of debt settlements relating to agreements with three trade vendors.  During the year ended December 31, 2010, the company incurred $337,900 of debt settlement expense related to the settlement of amounts owed to a third party the Company is no longer affiliated with.  Debt settlements such as these are not part of the Company’s normal course of business.


The following provides a description of the items included in these amounts.


 

2011

 

2010

Depreciation Expense

$

(149,754)

 

$

(150,608)

Amortization Expense

 

(18,611)

 

 

Interest Expense

 

(17,668)

 

 

(80,481)

Tax Expense

 

(13,267)

 

 

(23,409)

Debt Settlement

 

(8,409)

 

 

(337,900)

Other Income (Expense)

 

137 

 

 

(8.775)

 

 

 

 

 

 

Total Other Income and (Expense)

$

(207,572)

 

$

(601,173)




F-10




Note 9. Income Taxes


The Company follows ASC 740, Income Taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.


For the year ended December 31, 2011, the Company had a cumulative net operating loss carryover of approximately $1,152,339 available for U.S federal income tax, which expires beginning in 2017. The net operating loss carryovers may be subject to limitations under Internal Revenue Code due to significant changes in the Company’s ownership. The Company has provided a full valuation allowance against the full amount of the net operating loss benefit, since, in the opinion of management, based upon the earnings history of the Company, it is more likely than not that the benefits will not be realized.


Deferred net tax asset (34%) consists of the following at December 31, 2011:


 

2011

 

2010

Deferred tax asset

$

402,867 

 

$

388,000 

Less valuation allowance

 

(402,867)

 

 

(388,000)

Net deferred tax asset

$

 

$


A reconciliation between income taxes at statutory tax rates (34%) and the actual income tax provision for continuing operations as of December 31, 2011 follows:


 

2011

 

2010

Expected Provision (based on statutory rate)

$

(14,867)

 

$

(109,000)

Increase to deferred tax valuation allowance for net operating loss carry forward

 

14,867 

 

 

109,000 

Net provision

$

 

$


The Company has filed its tax returns through December 31, 2011.


The provisions of ASC 740 require companies to recognize in their financial statements the impact of a tax position if that position is more likely than not to be sustained upon audit, based upon the technical merits of the position. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken on a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods and disclosure.


Management does not believe that the Company has any material uncertain tax positions requiring recognition or measurement in accordance with the provisions of ASC 740. Accordingly, the adoption of these provisions of ASC 740 did not have a material effect on the Company’s financial statements. The Company’s policy is to record interest and penalties on uncertain tax positions, if any, as income tax expense.


All tax years for the Company remain subject to future examinations by the applicable taxing authorities because some taxes are still due and owing.


Note 10. Subsequent Events


On August 13, 2012, the Company entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with Diagnostic Imaging International Corp. (“DIIG”). Pursuant to the terms of the Share Purchase Agreement, DIIG is to purchase all of the outstanding capital stock of the Company for an aggregate purchase price of $1,950,000, plus a possible earn-out payment of up to $200,000 if certain post-closing revenue targets are met. Under the terms of the Share Purchase Agreement, DIIG has made a non-refundable payment of $20,000 to the Company, which will be credited against the purchase price at closing.


On October 11, 2012, the Company entered into an amendment of the Share Purchase Agreement with DIIG. The new amendment extends the closing date of the original transaction to November 29, 2012.  Upon execution of this amendment an additional non-refundable payment of $20,000 was made to the Company, which will be credited against the purchase price at closing.




F-11




INDEX TO FINANCIAL STATEMENTS


Balance Sheets as of September 30, 2012 and December 31, 2011

F-13

Statements of operations for the nine months ended September 30, 2012 and 2011

F-14

Statements of Cash Flows for the nine months ended September 30, 2012 and 2011

F-15

Notes to Financial Statements

F-16




F-12





SCHUYLKILL OPEN MRI, INC.

BALANCE SHEETS

(Unaudited)

 

 

 

 

 

 

 

September 30,

 

December 31,

 

2012

 

2011

ASSETS

 

 

 

 

 

Current Assets

 

 

 

 

 

Cash

$

67,915

 

$

19,259

Accounts Receivable, net

 

157,040

 

 

212,028

Prepaid expenses

 

2,237

 

 

-

Total Current Assets

 

227,192

 

 

231,287

 

 

 

 

 

 

Property and Equipment, net of accumulated depreciation

 

798,113

 

 

908,741

 

 

 

 

 

 

Other Assets

 

 

 

 

 

Security Deposit

 

66,715

 

 

8,140

Non-compete Agreement, net of accumulated amortization

 

31,639

 

 

48,389

Total Other Assets

 

98,354

 

 

56,529

TOTAL ASSETS

 

1,123,660

 

 

1,196,557

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

Current Liabilities

 

 

 

 

 

Accounts Payable and Accrued Liabilities

$

439,595

 

$

37,164

Related Party Payable

 

337,989

 

 

238,056

Current Portion of Long-term Debt

 

88,928

 

 

73,731

Total Current Liabilities

 

866,512

 

 

645,002

Notes payable

 

68,444

 

 

80,240

TOTAL LIABILITIES

 

934,956

 

 

725,242

 

 

 

 

 

 

STOCKHOLDERS' EQUITY

 

 

 

 

 

Common Stock - no par value - 1,000,000 shares authorized, 11,666 issued and outstanding

 

1,000

 

 

1,000

Additional Paid-in Capital

 

90,000

 

 

90,000

Retained Earnings

 

97,704

 

 

380,315

TOTAL STOCKHOLDERS' EQUITY

 

188,704

 

 

471,315

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$

1,123,660

 

$

1,196,557




F-13





SCHUYLKILL OPEN MRI, INC.

STATEMENTS OF OPERATIONS

FOR THE NINE MONTHS ENDED

(UNAUDITED)

 

 

 

 

 

 

 

September 30,

 

September 30,

 

2012

 

2011

REVENUE

 

 

 

 

 

SALES

$

1,397,437 

 

$

1,336,814 

LESS: Cost of Sales

 

457,691 

 

 

388,872 

Gross Margin

 

939,745 

 

 

947,942 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

Advertising

 

11,142 

 

 

9,639 

Amortization

 

16,750 

 

 

13,028 

Depreciation

 

171,649 

 

 

87,748 

General and administrative

 

202,958 

 

 

124,424 

Insurance

 

23,213 

 

 

21,610 

Legal and professional

 

44,737 

 

 

750 

Management fees

 

680,581 

 

 

674,527 

Rent

 

50,293 

 

 

46,566 

Travel

 

7,431 

 

 

2,765 

Total Operating Expenses

 

1,208,754 

 

 

981,058 

 

 

 

 

 

 

Net Gain from Operations

 

 

 

 

 

 

 

 

 

 

 

Other Income and (Expenses):

 

 

 

 

 

Other Income

 

1,493 

 

 

110,159 

Interest Expense

 

(15,094)

 

 

(48,956)

Total Other Income/(Expenses)

 

(13,601)

 

 

61,202 

 

 

 

 

 

 

Income / (Loss) Before Provision for Income Taxes

 

(282,610)

 

 

28,086 

Provision for Income Taxes

 

 

 

Net Income / (Loss)

$

(282,610)

 

$

28,086 




F-14





SCHUYLKILL OPEN MRI, INC.

STATEMENT OF CASH FLOWS

FOR THE NINE MONTHS ENDED

 

 

 

 

 

 

 

September 30,

 

September 30,

 

2012

 

2011

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

Net Income (loss)

$

(282,610)

 

$

28,086 

 

 

 

 

 

 

Adjustment to Reconcile Net Income (Loss) to Net Cash Provided by Operating Activities:

 

 

 

 

 

Bad Debt Expense

 

90,000 

 

 

Depreciation Expense

 

171,649 

 

 

87,748 

Amortization Expense

 

16,750 

 

 

13,028 

Debt Settlement

 

 

 

Changes in Assets and Liabilities

 

 

 

 

 

Accounts Receivable

 

54,988 

 

 

137,247 

Prepaid Expenses

 

(2,237)

 

 

Other Assets

 

(58,575)

 

 

Accounts Payable and Accrued Liabilities

 

106,380 

 

 

395,492 

Related Party Payable

 

(201,476)

 

 

(59,895)

Net Cash Provided by Operating Activities

 

177,479 

 

 

573,620 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

 

 

 

Acquisition of Goodwill

 

 

 

(448,889)

Acquisitions of Property and Equipment

 

(61,021)

 

 

(4,770)

Net Cash Used in Investing Activities

 

(61,021)

 

 

(453,659)

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

Payments of Capital Lease Obligations

 

 

 

(125,386)

Payments of Long-term Debt

 

304,810 

 

 

48,842 

Net Cash Used in Financing Activities

 

304,810 

 

 

(76,544)

 

 

 

 

 

 

Net Increase (Decrease) in Cash

 

138,658 

 

 

71,503 

 

 

 

 

 

 

Cash - Beginning of year

 

19,259 

 

 

14,484 

 

 

 

 

 

 

Cash - End of Year

$

67,915 

 

$

19,017 





F-15




Schuylkill Open MRI, Inc.

Notes to Financial Statements

September 30, 2012


Note 1 Organization and Summary of Significant Accounting Policies


Organization and Basis of Presentation


Schuylkill Open MRI, Inc. (“Schuylkill”, the “Company”, “us”, or “we”) was incorporated on April 24, 2001 under the laws of the State of Texas.  Schuylkill is an independent diagnostic testing facility located in Pottsville, Pennsylvania providing Magnetic Resonance Imaging (MRI) services and which is unaffiliated with any hospital or medical group. Schuylkill officially opened for business and began its operations in March 2003 as an outpatient open MRI facility. Schuylkill currently performs exams on its Siemens Concerto OPEN MRI System utilizing Siemens’ Syngo software (“OPEN MRI”) and its Siemens Magnetom Symphony Quantum 1.5T high field MRI System, also utilizing Syngo software (“Symphony 1.5T high field MRI”).   In April 2012, Schuylkill replaced its Magnetom Vision 1.5T high field MRI (“Vision MRI”) with a refurbished Symphony 1.5T high field MRI. Having both the OPEN MRI System and the Symphony 1.5T high field MRI gives Schuylkill flexibility in the studies it can conduct. Schuylkill uses an electronic health record system to manage its patient medical records.  Schuylkill offers same day, evening and Saturday appointments to accommodate emergency and non-emergency patient’s schedule needs.


Schuylkill participates in most major insurance plans. Schuylkill also accepts Medicare, Medicaid, Worker’s Compensation claims, Personal Injury Protection and Letters of Protection for participating personal injury attorneys in the area. Schuylkill is accredited by the American College of Radiology (“ACR”) and by the Intersocietal Accreditation Commission (or “ICAMRL”). The ACR certification is valid through March 3rd, 2015 and the ICAMRL certification is valid through March 31st, 2015.


Basis of Presentation


These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year-end is December 31.


Use of Estimates and Assumptions


The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales, expenses and costs recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.


Cash and Cash Equivalents


The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At September 30, 2012 cash includes cash on hand and cash in the bank.


Accounts Receivable Credit Risk


The allowance for doubtful accounts is maintained at a level sufficient to provide for estimated credit losses based on evaluating known and inherent risks in the receivables portfolio.


Management evaluates various factors including expected losses and economic conditions to predict the estimated realization on outstanding receivables. As of September 30, 2012 and December 31, 2011, the allowance for bad debts was $386,361 and $296,361 respectively.




F-16




Goodwill and Indefinite Intangible Assets


The Company follows the provisions of Financial Accounting Standard (“FASB”) Accounting Standards Codification (“ASC”) Topic 350 Goodwill and Other Intangible Assets. In accordance with ASC Topic 350, goodwill represents the excess of the purchase price and related costs over the value assigned to net tangible and identifiable intangible assets of businesses acquired and accounted for under the purchase method. Under this standard, goodwill and intangibles with indefinite useful lives are not amortized.  The Company assesses goodwill and indefinite-lived intangible assets for impairment annually during the fourth quarter, or more frequently if events and circumstances indicate impairment may have occurred in accordance with ASC Topic 350. If the carrying value of a reporting unit's goodwill exceeds its implied fair value, the Company records an impairment loss equal to the difference. ASC Topic 350 also requires that the fair value of indefinite-lived purchased intangible assets be estimated and compared to the carrying value. The Company recognizes an impairment loss when the estimated fair value of the indefinite-lived purchased intangible assets is less than the carrying value.  As of September 30, 2012, the Company has not acquired any indefinite-lived intangible assets and goodwill.


Revenue Recognition


The Company recognizes revenue at the time of service.


Revenue is accounted for under the guidelines established by SAB 101, Revenue Recognition in Financial Statements, and ASC Topic 605-45, Revenue Recognition – Principal Agent Considerations.


Cost of Sales


Cost of sales includes fees paid to radiologists for Teleradiology services and system usage costs.


Impairment of Long-Lived Assets


In accordance with ASC Topic 360, Property, Plant and Equipment, property, plant, and equipment, and purchased intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.


No impairment loss was recorded for the periods ended September 31, 2012 and 2011.


Amortization and Depreciation


Depreciation and amortization are calculated using the straight-line method over the following useful lives:


Medical Equipment – 5 – 7 years


Furniture and Fixtures – 5 – 7 years


Leasehold Improvements – 39 years


Fair Value of Financial Instruments


The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties other than in a forced sale or liquidation.


The carrying amounts of the Company’s financial instruments, including cash, accounts receivable, accounts payable and accrued liabilities, and income taxes payable approximate fair value due to their most maturities.




F-17




Fair Value Measurements


The hierarchy below lists three levels of fair values based on the extent to which inputs used in measuring fair value is observable in the market. We disclose and categorize each of our fair value measurement items that we recorded at fair value on a recurring basis in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:


• Level 1—inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Our Level 1 non-derivative investments primarily include domestic and international equities, U.S. treasuries and agency securities, and exchange-traded mutual funds. Our Level 1 derivative assets and liabilities include those traded on exchanges.


• Level 2—inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques (e.g. the Black-Scholes model) for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, foreign exchange rates, and forward and spot prices for currencies and commodities. Our Level 2 non-derivative investments consist primarily of corporate notes and bonds, mortgage-backed securities, certificates of deposit, certain agency securities, foreign government bonds, and commercial paper. Our Level 2 derivative assets and liabilities primarily include certain over-the-counter options, futures, and swap contracts.


• Level 3—inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models. Our Level 3 non-derivative assets primarily comprise investments in certain corporate bonds. We value these corporate bonds using internally developed valuation models, inputs to which include interest rate curves, credit spreads, stock prices, and volatilities. Unobservable inputs used in these models are significant to the fair values of the investments. The Company Level 3 derivative assets and liabilities primarily comprise derivatives for foreign equities. In certain cases, market-based observable inputs are not available and the company uses management judgment to develop assumptions to determine fair value for these derivatives.


The company does not have assets and liabilities that are carried at fair value on a recurring basis.


Income Taxes


The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes.  This statement prescribes the use of the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.


Recent Accounting Updates


Recent accounting updates that the Company has adopted or that will be required to adopt in the future are summarized below.


On December 31, 2011, the Company adopted updates issued by the Financial Accounting Standards Board (FASB) to the authoritative hierarchy of GAAP. These changes establish the FASB Accounting Standards Codification (ASC) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP. Rules and interpretive releases of the Securities and Exchange Commission (“SEC”) under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. The FASB will no longer issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts; instead the FASB will issue Accounting Standards Updates. Accounting Standards Updates will not be authoritative in their own right as they will only serve to update the Codification. These changes and the Codification itself do not change GAAP. Other than the manner in which new accounting guidance is referenced, the adoption of these changes had no impact on the Financial Statements.


The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.


Updates issued but not yet adopted


The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.




F-18




Note 2. Property and Equipment


Property and equipment are stated at cost.   At September 31, 2012 and December 31, 2011, the major classes of property and equipment were as follows:


 

September 30,

2012

 

December 31,

2011

Medical Equipment

$

922,915 

 

$

1,017,450 

Furniture and Fixtures

 

60,842 

 

 

39,180 

Leasehold Improvements

 

1,004,031 

 

 

946,803 

Less: Accumulated Depreciation

 

(1,189,675)

 

 

(1,094,692)

Property and Equipment - Net

$

798,113 

 

$

908,741 


Depreciation expense was $171,654 for the nine months ended September 30, 2012.


Note 3. Lease Commitments


During 2011, the Company extended their current facilities lease for an additional five years.  The lease called for initial lease payments of $4,390 per month with annual increases based on the larger of 2% or the Consumer Price Index as defined.  As September 31, 2012, the monthly lease payment was $5,185.  Total lease expense, including late fees and incidental charges, for the nine months ending September 30, 2012 and 2011 was $50,293 and $46,566, respectively.


Note 4. Related Party Payables and Expenses


As of September 30, 2012 and December 31, 2011, the Company owed related entities $337,989 and $238,056, respectively.


Of these amounts, the Company owed Metiscan Holdings, Inc.(“Holdings”) $337,989 and $238,056, as of September 30, 2012 and December 31, 2011, respectively. Holdings is a majority shareholder and is operated by the Company’s management team.  The Company pays Holdings a management fee equal to 5% of earnings each month. During the nine months ended September 30, 2012 and 2011, the Company recorded management fee expense of $328,881 and $313,682, respectively.


The Company leases all its employees from an employee leasing company, Shoreline Employment Services, Inc., (“Shoreline”).  Shoreline is operated by the Company’s management team.  During the nine months ended September 30, 2012 and 2011, the Company recorded employee leasing expense of $351,700 and $360,846, respectively.


From time to time, the Company is required to reimburse Bridgepoint Partners, LLC (“Bridgepoint”) for business expenses paid on behalf of the Company.  Bridgepoint is operated by a member of the Company’s management team.  As of September 30, 2012 and December 31, 2011, the Company owed Bridgepoint $0 and $2,342, respectively.


Note 5. Accrued Expenses


As of September 30, 2012 and December 31, 2011, the accrued expenses of the Company were $266,284 and $296,051, respectively.


Of this amount, $141,950 and $124,334, as of September 30, 2012 and December 31, 2011, respectively, was due to the state of Pennsylvania for unpaid corporate income taxes.


The balance of, $124,334, as of September 30, 2012 and December 31, 2011, respectively, was due to the federal government for unpaid corporate income taxes.


Note 6. Obligations under Capital Lease


On January 1, 2008, the Company entered into a Master Equipment Lease Agreement with Tygris Asset Finance in the amount of $492,970 to finance the purchase of the Company’s Vision MRI located at its facility as well as the leasehold improvements that were made to the facility to accommodate the equipment. This “dollar -buyout” lease has a term of four (4) years at a rate of eight and four tenths of a percent (8.40%) per annum beginning on January 1, 2008 and maturing on January 1, 2012. The monthly payment on this lease was $11,076.


The lease was paid in full on December 14, 2011 and no future minimum lease payments remain at December 31, 2011.


The gross amount of equipment held under capital leases totals $861,383 ($0 net book value after accumulated depreciation of $861,383) at December 31, 2011 and 2010.



F-19





Note 7. Long-Term Debt


On May 5, 2009, the Company borrowed $190,000 from JPMorgan Chase Bank and issued a promissory note that calls for a term of four (4) years at a rate of six and a tenth of a percent (6.10%) per annum beginning on June 5, 2009 and maturing on May 5, 2013. The loan was established to refinance the Company’s OPEN MRI that is located at its facility. The monthly payment on this promissory note is $4,479. As of September 30, 2012 and December 31, 2011, the unpaid balance of this note was $30,638 and $68,545, respectively.


On June 19, 2009, the Company borrowed $50,000 from an individual and issued a promissory note that calls for a term of five (5) years at a rate of ten percent and one-half of one percent (10.5%) per annum beginning on July 10, 2009, and maturing on April 10, 2014. The monthly payment on this promissory note is $1,074. As of September 30, 2012 and December 31,2011, the unpaid balance of this note was $20,535 and $28,248, respectively.


On February 28, 2011, the Company entered into a non-compete agreement with a former employee and issued a promissory note in the amount of $67,000 that calls for a term of five (5) years at a rate of six percent (6%) per annum beginning on April 1, 2011, and maturing on March 1, 2016. The monthly payment on this promissory note is $1,295. As of September 30, 2012, the unpaid balance of this note was $47,910.


On February 26, 2012, the Company issued a promissory note of $55,000 payable on demand at a rate of 10% per annum, paid monthly.


Following are maturities of the long –term debt in convertible notes for each of the next 5 years:


December 31, 2012

 

$

73,731

December 31, 2013

 

 

38,272

December 31, 2014

 

 

24,497

December 31, 2015

 

 

14,901

December 31, 2016

 

 

2,570

Total

 

$

153,971


Interest expense related to long-term debt for the years ended September 30, 2012 and December 31, 2011 was $11,162 and $12,416, respectively.


Note 8. Subsequent Events


On December 10, 2012, Diagnostic Imaging International Corp. (“Diagnostic”) completed the purchase of the Company.  Diagnostic is an SEC registrant and has reported this purchase on an 8K filed on December 12, 2012.



F-20




SCHUYLKILL OPEN MRI, INC, CANADIAN TELERADIOLOGY SERVICES, INC. AND DIAGNOSTIC IMAGING INTERNATIONAL CORP.

Unaudited Pro forma Condensed Combined Financial Information

December 31, 2011 and September 30, 2012


The following unaudited pro forma condensed combined balance sheet, pro forma condensed combined statements of operations and explanatory notes give effect to the acquisition of Schuylkill Open MRI, Inc. (“SOMRI”) by Diagnostic Imaging International Corp. (“DIIC”).


The unaudited pro forma condensed combined balance sheet, pro forma condensed combined statements of operations and explanatory notes are based on the estimates and assumptions set forth in the explanatory notes. The pro forma condensed combined balance sheet and the pro forma condensed combined statements of operations have been prepared utilizing the historical financial statements of SOMRI and DIIC and should be read in conjunction with the historical financial statements and notes thereto.


The transaction giving rise to the consolidated entity is a purchase by Diagnostic of a 100% interest in SOMRI in December, 2012 in consideration for cash, and contingent liability.


The pro forma condensed combined statements of operations have been prepared as if the acquisition had been consummated on January 1, 2011 and carried through to September 30, 2012.  The pro forma condensed combined balance sheet has been prepared as if the acquisition was consummated as of the balance sheet date.


The condensed combined financial statements are presented for informational purposes only, are based on certain assumptions that we believe are reasonable and do not purport to represent our financial condition or our results of operations had the business combination occurred on or as of the dates noted above or to project the results for any future date or period. In the opinion of management, all adjustments have been made that are necessary to present fairly the unaudited condensed combined financial information.


The acquisition and related transactions will be treated as a purchase business combination for accounting purposes, and SOMRI’s assets acquired and liabilities assumed will be recorded at their fair value.


The allocations of the purchase price to SOMRI’s assets and liabilities are only preliminary allocations based on estimates of fair value and will change when the actual fair values are determined.  Among the provisions of Statement of Financial Accounting Standards No. 141(R), "Business Combinations," criteria have been established for determining whether intangible assets should be recognized separately from goodwill.









Diagnostic Imaging International Corp.

Unaudited Pro Forma Balance Sheets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

DIIC

 

CTS

 

SOMRI

 

Consolidating

 

Consolidating

 

Consolidated

 

December 31,

 

December 31,

 

December 31,

 

Entries

 

Entries

 

December 31,

 

2011

 

2011

 

2011

 

CTS

 

SOMRI

 

2011

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash

15,254 

 

39,251 

 

19,259 

 

 

 

 

 

$

73,764 

Accounts Receivable, net

12,135 

 

137,744 

 

212,027 

 

(12,135)

 

 

 

 

349,771 

Prepaid Expenses

 

7,144 

 

 

 

 

 

 

 

7,144 

Total Current Assets

27,389 

 

184,139 

 

231,286 

 

(12,135)

 

 

 

430,679 

Property and Equipment

 

 

 

 

 

 

 

 

 

 

 

 

Equipment

8,955 

 

102,336 

 

2,003,433 

 

(8,155)

 

 

 

 

2,106,569 

Less: Accumulated Depreciation

(680)

 

(101,082)

 

(1,094,692)

 

 

 

 

 

 

(1,196,454)

Total Property and Equipment, net

8,275 

 

1,254 

 

908,741 

 

(8,155)

 

 

 

910,115 

Goodwill

 

 

 

 

967,168 

3

 

967,168 

Intangibles

 

 

 

 

 

 

 

 

 

 

 

 

Hospital Contracts

794,707 

 

 

 

 

 

 

794,707 

Contract

105,328 

 

 

67,000 

 

 

 

 

 

 

172,328 

Less: Accumulated Amortization

(650,406)

 

 

(18,611)

 

 

 

 

(669,017)

Total Intangible Assets, net

249,629 

 

 

48,389 

 

 

967,168 

 

 

1,265,186 

Other Assets

 

 

 

 

 

 

 

 

 

 

 

 

Intercompany Loan

(97,117)

 

 

 

97,117 

 

 

 

 

Deposits

 

4,932 

 

8,140 

 

 

 

 

 

 

13,072 

Loans Receivable

 

968 

 

 

 

 

 

 

 

968 

Total Other Assets

(97,117)

 

5,900 

 

8,140 

 

97,117 

  

 

 

14,040 

TOTAL ASSETS

188,176 

 

191,293 

 

1,196,556 

 

76,827 

 

967,168 

 

$

2,620,020 










Diagnostic Imaging International Corp.

Unaudited Pro Forma Balance Sheets

(continued)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

DIIC

 

CTS

 

SOMRI

 

Consolidating

 

Consolidating

 

Consolidated

 

December 31,

 

December 31,

 

December 31,

 

Entries

 

Entries

 

December 31,

 

2011

 

2011

 

2011

 

CTS

 

SOMRI

 

2011

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Accounts Payable and Accrued Expenses

235,243 

 

159,480 

 

333,218 

 

(172,250)

 

(317,448)

2

$

238,243 

Promissory Notes

84,591 

 

 

 

 

 

 

 

 

84,591 

Loan Payable - Related Party

 

 

238,056 

 

 

 

(238,056)

2

 

Note Payable - Shareholder

7,062 

 

(60,957)

 

 

60,957 

 

 

 

 

7,062 

Current Portion of Long Term Debt

 

 

73,730 

 

 

 

 

 

 

73,730 

Convertible Note - Shareholder, net short term portion

19,960 

 

 

 

 

 

 

 

19,960 

Convertible Notes, net short term portion

166,333 

 

 

 

 

 

 

 

 

166,333 

Total Current Liabilities

513,189 

 

98,523 

 

645,004 

 

(111,293)

 

(555,504)

 

 

589,919 

Long Term Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Obligations in excess of Cash Balance

 

 

 

 

 

 

 

 

1,825,000 

1

 

1,825,000 

Contingent Liability

 

 

 

 

 

 

 

 

200,000 

1

 

200,000 

Long Term Note

 

 

80,240 

 

 

 

 

 

 

80,240 

Convertible Note - Shareholder, net

 

 

 

 

 

 

 

 

Convertible Notes, net  

 

 

 

 

 

 

 

 

Total Long Term Liabilities

 

 

80,240 

 

 

 

2,025,000 

 

 

2,105,240 

Total Liabilities

513,189 

 

98,523 

 

725,241 

 

(111,293)

 

1,469,496 

 

 

2,695,159 

Stockholders' Equity

 

 

 

 

 

 

 

 

 

 

 

 

Preferred Stock-$0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding

 

 

 

 

 

 

 

 

Common Stock-$0.001 par value; 100,000,000 shares authorized, 18,106,481, shares issued and outstanding at December 31, 2011

18,107 

 

10 

 

1,000 

 

(10)

 

(1,000)

1

 

18,107 

Additional Paid-In Capital

1,597,413 

 

38,505 

 

90,000 

 

(38,505)

 

(90,000)

1

 

1,597,413 

Comprehensive Loss Accumulated

108 

 

(1,822)

 

 

4,516 

 

 

 

 

2,802 

Accumulated Deficit

(1,940,641)

 

56,077 

 

380,314 

 

222,119 

 

(411,328)

1

 

(1,693,461)

Total Stockholders' Equity

(325,013)

 

92,770 

 

471,314 

 

188,120 

  

(502,328)

 

 

(75,139)

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

188,176 

 

191,293 

 

1,196,556 

 

76,827 

 

(967,168)

 

$

2,620,020 


1) To record consideration given per acquisition agreement.

2) To reduce payables and debt to maximum amounts per the acquisition agreement.

3) To record Goodwill as if the transaction took place as of 1/1/2011.








Diagnostic Imaging International Corp.

Unaudited Pro Forma Statements of Operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

DIIC

 

CTS

 

SOMRI

 

Consolidating

 

Consolidating

 

Consolidated

 

December 31,

 

December 31,

 

December 31,

 

Entries

 

Entries

 

December 31,

 

2011

 

2011

 

2011

 

CTS

 

SOMRI

 

2011

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales

$

 

$

3,536,176 

 

$

1,787,614 

 

 

 

 

 

$

5,323,790 

Less: Cost of sales

 

 

 

2,905,077 

 

 

533,531 

 

 

 

 

 

 

3,438,608 

Gross Margin

 

 

 

631,099 

 

 

1,254,083 

 

 

 

 

 

 

1,885,182 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Advertising

 

827 

 

 

495 

 

 

10,897 

 

 

 

 

 

 

12,219 

Amortization

 

115,213 

 

 

 

 

18,611 

 

 

 

 

 

 

133,824 

Depreciation

 

160 

 

 

1,266 

 

 

149,755 

 

 

 

 

 

 

151,181 

Impairment Loss

 

 

 

 

 

 

 

 

 

 

 

General and Administrative

 

12,875 

 

 

34,058 

 

 

119,243 

 

 

 

 

 

 

166,176 

Insurance

 

 

 

19,806 

 

 

28,658 

 

 

 

 

 

 

48,464 

Labor

 

 

 

120,644 

 

 

 

 

 

 

 

 

120,644 

Legal and professional

 

48,669 

 

 

49,200 

 

 

351 

 

 

 

 

 

 

98,220 

Management fees

 

9,632 

 

 

 

 

870,864 

 

 

 

 

 

 

880,496 

Rent Office Space and Servers

 

 

 

94,800 

 

 

62,770 

 

 

 

 

 

 

157,570 

Travel

 

1,509 

 

 

4,857 

 

 

6,614 

 

 

 

 

 

 

12,980 

Total Operating Expenses

 

188,885 

 

 

325,126 

 

 

1,267,763 

 

 

 

 

 

 

1,781,774 

Net Gain / (Loss) from Operations

 

(188,885)

 

 

305,973 

 

 

(13,680)

 

-

 

-

 

 

103,408 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income and (Expenses):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income

 

6,510 

 

 

247 

 

 

333 

 

 

 

 

 

 

7,090 

Foreign Currency Gains/(Losses)

 

(291)

 

 

 

 

 

 

 

 

 

 

(291)

Settlement on Business Combination

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

(105,145)

 

 

 

 

 

 

 

 

 

 

(105,145)

Interest Expense

 

(37,119)

 

 

(721)

 

 

(17,669)

 

 

 

 

 

 

(55,509)

Total Other Income/(Expenses)

 

(136,045)

 

 

(474)

 

 

(17,336)

 

 

 

 

 

 

(153,855)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Income Before Provision for Income Taxes

 

(324,930)

 

 

305,499 

 

 

(31,016)

 

 

 

 

 

 

(50,447)

Provision for Income Taxes

 

 

 

(60,728)

 

 

 

 

 

 

 

 

(60,728)

Net Income

 

(324,930)

 

 

244,771 

 

 

(31,016)

 

 

 

 

 

 

(111,175)

Comprehensive Income

 

 

 

 

 

 

4,205

 

 

 

 

4,205 

Total comprehensive Loss

$

(324,930)

 

 

244,770 

 

 

(31,016)

 

4,205

 

 

 

$

(106,971)

Basic and Diluted Income / (Loss) per Share

$

(0.018)

 

 

 

 

 

 

 

 

 

 

 

$

(0.006)

Weighted Average Shares Outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted

 

18,106,481 

 

 

 

 

 

 

 

 

 

 

 

 

18,073,056 


The accompanying notes are an integral part of these consolidated financial statements.







Diagnostic Imaging International Corp.

Unaudited Pro Forma Balance Sheets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

DIIC

 

CTS

 

SOMRI

 

Consolidating

 

Consolidating

 

Consolidated

 

September 30,

 

September 30,

 

September 30,

 

Entries

 

Entries

 

September 30,

 

2012

 

2012

 

2012

 

CTS

 

SOMRI

 

2012

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

$

125,328 

 

 

28,389 

 

 

67,915 

 

 

 

 

 

$

221,632 

Accounts Receivable, net

 

12,135 

 

 

160,840 

 

 

157,040 

 

(12,135)

 

 

 

 

317,880 

Prepaid Expenses

 

 

 

5,179 

 

 

2,237 

 

 

 

 

 

 

7,416 

Total Current Assets

 

137,463 

 

 

194,408 

 

 

227,192 

 

(12,135)

 

 

 

546,928 

Property and Equipment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equipment

 

8,955 

 

 

74,309 

 

 

1,987,789 

 

(8,155)

 

 

 

 

2,062,898 

Less: Accumulated Depreciation

 

(800)

 

 

(70,596)

 

 

(1,189,675)

 

 

 

 

 

 

(1,261,071)

Total Property and Equipment, net

 

8,155 

 

 

3,713 

 

 

798,114 

 

(8,155)

 

 

 

801,827 

Goodwill

 

 

 

 

 

 

 

967,168 

3

 

967,168 

Intangibles

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hospital Contracts

 

794,707 

 

 

 

 

 

 

 

 

 

 

794,707 

Non-Compete Contract

 

105,328 

 

 

 

 

67,000 

 

 

 

 

 

 

172,328 

Less: Accumulated Amortization

 

(736,816)

 

 

 

 

(35,361)

 

 

 

 

 

 

(772,177)

Total Intangible Assets,net

 

163,219 

 

 

 

 

31,639 

 

 

967,168 

 

 

1,162,026 

Other Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Intercompany Loan

 

(312,490)

 

 

 

 

 

312,490 

 

 

 

 

Deposits

 

 

 

5,099 

 

 

66,715 

 

 

 

 

 

 

71,814 

Restricted Deposit

 

20,000 

 

 

 

 

 

 

 

 

 

 

20,000 

Loans Receivable

 

 

 

3,177 

 

 

 

 

 

 

 

 

3,177 

Total Other Assets

 

(292,490)

 

 

8,276 

 

 

66,715 

 

312,490 

 

 

 

94,991 

TOTAL ASSETS

$

16,347 

 

$

206,397 

 

$

1,123,660 

 

292,200 

 

967,168 

 

$

2,605,772 










Diagnostic Imaging International Corp.

Unaudited Pro Forma Balance Sheets

(continued)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

DIIC

 

CTS

 

SOMRI

 

Consolidating

 

Consolidating

 

Consolidated

 

September 30,

 

September 30,

 

September 30,

 

Entries

 

Entries

 

September 30,

 

2012

 

2012

 

2012

 

CTS

 

SOMRI

 

2012

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts Payable and Accrued Expenses

 

212,195 

 

 

237,143 

 

 

439,595 

 

(172,250)

 

(96,723)

2

$

619,960 

Promissory Notes

 

120,029 

 

 

 

 

 

 

 

 

 

 

120,029 

Loans Payable

 

100,000 

 

 

 

 

 

 

 

 

 

 

100,000 

Loan Payable – Related Party

 

 

 

 

 

36,580 

 

 

 

 

 

 

36,580 

Note Payable

 

 

 

 

 

 

 

 

 

 

 

Note Payable – Shareholder

 

7,062 

 

 

(281,984)

 

 

 

281,984 

 

 

 

 

7,062 

Convertible Note – Shareholder, net short term portion

 

15,029 

 

 

 

 

 

 

 

 

 

15,029 

Convertible Notes, net short term portion

 

106,111 

 

 

 

 

 

 

 

 

 

 

106,111 

Total Current Liabilities

 

560,426 

 

 

(44,841)

 

 

476,175 

 

109,734 

-

(96,723)

 

 

1,004,771 

Long Term Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Obligations in excess of Cash Balance

 

 

 

 

 

 

 

 

 

 

 

1,825,000 

1

 

1,825,000 

Contingent Liability

 

 

 

 

 

 

 

 

 

 

 

200,000 

1

 

200,000 

Long Term Note

 

 

 

 

 

 

 

 

 

 

 

 

Convertible Note – Shareholder, net

 

 

 

 

 

 

 

 

 

 

 

Convertible Notes, net  

 

 

 

 

 

458,781 

 

 

 

(458,781)

2

 

Total Long Term Liabilities

 

 

 

 

 

458,781 

 

 

 

1,566,219 

 

 

2,025,000 

Total Liabilities

 

560,426 

 

 

(44,841)

 

 

934,956 

 

109,734 

 

1,469,496 

 

 

3,029,771 

Stockholders’ Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred Stock-$0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding

 

 

 

 

 

 

 

 

 

 

 

Common Stock-$0.001 par value; 100,000,000 shares authorized, 18,106,481, shares issued and outstanding at September 30, 2012

 

18,107 

 

 

10 

 

 

1,000 

 

(10)

 

(1,000)

1

 

18,107 

Additional Paid-In Capital

 

1,597,943 

 

 

39,809 

 

 

90,000 

 

(39,809)

 

(90,000)

1

 

1,597,943 

Comprehensive Loss Accumulated

 

108 

 

 

3,017 

 

 

 

142 

 

 

 

 

3,267 

Accumulated Deficit

 

(2,160,235)

 

 

208,400 

 

 

97,704 

 

222,143 

 

(411,328)

1

 

(2,043,316)

Total Stockholders’ Equity

 

(544,077)

 

 

251,236 

 

 

188,704 

 

182,466 

-

(502,328)

 

 

(423,999)

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

16,349 

 

$

206,395 

 

$

1,123,660 

 

292,200 

-

967,168 

 

$

2,605,772 


The accompanying notes are an integral part of these consolidated financial statements.


1) To record consideration given per acquisition agreement.

2) To reduce payables and debt to maximum amounts per the acquisition agreement.

3) To record Goodwill as if the transaction took place as of 1/1/2011.







Diagnostic Imaging International Corp.

Unaudited Pro Forma Statements of Operations

For the Nine Months Ended

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

DIIC

 

CTS

 

SOMRI

 

Consolidating

 

Consolidating

 

Consolidated

 

September 30,

 

September 30,

 

September 30,

 

Entries

 

Entries

 

September 30,

 

2012

 

2012

 

2012

 

CTS

 

SOMRI

 

2012

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales

$

 

$

2,488,697 

 

$

1,397,437 

 

 

 

 

 

$

3,886,134 

Less: Cost of sales

 

 

 

2,034,045 

 

 

457,691 

 

 

 

 

 

 

2,491,736 

Gross Margin

 

 

 

454,652 

 

 

939,746 

 

 

 

 

 

 

1,394,398 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Advertising

 

3,681 

 

 

1,128 

 

 

11,142 

 

 

 

 

 

 

15,951 

Amortization

 

86,410 

 

 

 

 

16,750 

 

 

 

 

 

 

103,160 

Depreciation

 

120 

 

 

1,377 

 

 

171,649 

 

 

 

 

 

 

173,146 

Impairment Loss

 

 

 

 

 

 

 

 

 

 

 

 

General and Administrative

 

12,299 

 

 

26,190 

 

 

202,958 

 

 

 

 

 

 

241,447 

Insurance

 

 

 

 

15,496 

 

 

23,213 

 

 

 

 

 

 

38,709 

Labor

 

 

 

 

87,066 

 

 

 

 

 

 

 

 

87,066 

Legal and professional

 

66,735 

 

 

28,397 

 

 

44,737 

 

 

 

 

 

 

139,869 

Management fees

 

7,169 

 

 

 

 

680,581 

 

 

 

 

 

 

687,750 

Rent Office Space and Servers

 

 

 

 

69,723 

 

 

50,293 

 

 

 

 

 

 

120,016 

Travel

 

3,500 

 

 

2,559 

 

 

7,431 

 

 

 

 

 

 

13,490 

Total Operating Expenses

 

179,914 

 

 

231,936 

 

 

1,208,754 

 

 

-

 

 

1,620,604 

Net Gain / (Loss) from Operations

 

(179,914)

 

 

222,716 

 

 

(269,008)

 

 

-

 

 

(226,206)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income and (Expenses):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income

 

19,945 

 

 

297 

 

 

1,493 

 

 

 

 

 

 

21,735 

Foreign Currency Gains/(Losses)

 

(8,251)

 

 

 

 

 

 

 

 

 

 

 

 

(8,251)

Settlement on Business Combination

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

(33,953)

 

 

 

 

 

 

 

 

 

 

 

 

(33,953)

Interest Expense

 

(17,421)

 

 

(1,293)

 

 

(15,094)

 

 

 

 

 

 

(33,808)

Total Other Income/(Expenses)

 

(39,680)

 

 

(996)

 

 

(13,601)

 

 

-

 

 

(54,277)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Income Before Provision for Income Taxes

 

(219,594)

 

 

221,720 

 

 

(282,609)

 

 

-

 

 

(280,483)

Provision for Income Taxes

 

 

 

(60,728)

 

 

 

 

 

 

 

 

(60,728)

Net Income

 

(219,594)

 

 

160,992 

 

 

(282,610)

 

 

 

 

 

 

(341,212)

Comprehensive Income/(Loss)

 

 

 

 

3,017 

 

 

 

(2,796)

 

 

 

 

221 

Total comprehensive Loss

$

(219,594)

 

 

164,009 

 

 

(282,610)

 

(2,796)

 

-

 

$

(340,991)

Basic and Diluted Income / (Loss) per Share

$

(0.012)

 

 

 

 

 

 

 

 

 

 

 

$

(0.019)

Weighted Average Shares Outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted

 

18,106,481 

 

 

 

 

 

 

 

 

 

 

 

 

18,106,481 


The accompanying notes are an integral part of these consolidated financial statements.









SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.


 

Diagnostic Imaging International Corp.

 

(Registrant)

 

 

 

 

 

 

 

 

 

Dated:  February 25, 2013

By:

/s/ Mitch Geisler

 

 

Name:  Mitch Geisler

 

 

Title: CEO